Reuters logo
BRIEF-Alexion interim CEO says looking for opportunities in M&A front
February 16, 2017 / 5:21 PM / in 10 months

BRIEF-Alexion interim CEO says looking for opportunities in M&A front

Feb 16 (Reuters) - Alexion Pharmaceuticals Inc -

* Alexion CFO says “we’re preparing for potential tax reform”: conf call

* Alexion chief commercial officer says soliris has broad IP extending into the next decade & expect additional patents in the next 12-18 months: conf call

* Alexion interim CEO says previously communicated guidance (from prioir management) for 2018 cannot be relied on, but too early for Co to present new projections

* Alexion exec says Co isn’t going to add patients to ongoing sbc103 study nor start new studies until “we really understand what’s happening” in the trial

* Alexion exec says co is unsatisfied with kanuma launch uptake thus far, hurt primarily by low diagnostic testing rates

* Alexion interim CEO: “I‘m 150% committed to the interim role because it doesn’t feel interim. I can tell you that, but I‘m all-in.”

* Alexion interim CEO says co is active on the business development front and is looking at opportunities Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below